Cabozantinib Improves PFS in Patients with Previously Treated, Progressive Advanced Extrapancreatic or Pancreatic Neuroendocrine Tumours By Ogkologos - October 25, 2024 941 0 Facebook Twitter Google+ Pinterest WhatsApp Findings from the CABINET study Source RELATED ARTICLESMORE FROM AUTHOR Giredestrant plus everolimus prolongs PFS among patients with ER-positive, HER2-negative, ESR1-mutated advanced breast cancer after the receipt of a CDK4/6 inhibitor EMA Recommends Granting a Marketing Authorisation for Ensartinib Taking on the RAS Challenge MOST POPULAR Aspartame and cancer – sweet nothings? July 14, 2023 Complete Cancer Prevalence in Europe in 2020 Reveals an Increased Proportion... February 1, 2024 Exosomes May Help Tumors Evade Immune System September 7, 2018 ESMO Targeted Anticancer Therapies Congress 2023 February 24, 2023 Load more HOT NEWS The Lung Immune Prognostic Index May Indicate Response to Immune Checkpoint... Withdrawal of Application to Change the Marketing Authorisation for Atezolizumab Progress in Treating Liver Cancer and Biliary Tract Cancer with Immunotherapy:... Opportunity and mentorship: Our new PhD programme aiming to open-up academia...
